Andrew Lawrence Taylor - 07 Aug 2025 Form 4 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Role: Chief Financial Officer
Signature: /s/ Andrew Taylor
Issuer symbol: OBIO
Transactions as of: 07 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 08 Aug 2025, 19:18:08 UTC
Previous filing: 13 Jun 2025
Next filing: 25 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Taylor Andrew Lawrence	Chief Financial Officer	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE	/s/ Andrew Taylor	08 Aug 2025	0001723889

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OBIO	Common Stock, par value $0.0001 per share ("Common Stock")	Award	$0	+80,000	+20%	$0.000000	480,788	07 Aug 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of restricted stock units ("RSUs") to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after the Grant Date, (ii) 33.33% of the shares will vest 30 months after the Grant Date, and (iii) 33.34% of the shares will vest 36 months after the Grant Date, subject to the Reporting Person's continuous service through such dates.

Content

Represents an award of restricted stock units ("RSUs") to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after the Grant Date, (ii) 33.33% of the shares will vest 30 months after the Grant Date, and (iii) 33.34% of the shares will vest 36 months after the Grant Date, subject to the Reporting Person's continuous service through such dates.